MétaCan
Menu
Back to cohort
Record W4415885203 · doi:10.1002/ejhf.70083

Finerenone in Patients with Severe Heart Failure: The FINEARTS-HF Trial

2025· article· en· W4415885203 on OpenAlexaff
Riccardo M. Inciardi, Henri Lu, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair D Henderson, Béla Merkely, Michele Senni, Sanjiv J. Shah, Kavita Sharma, Orly Vardeny, Mark C. Petrie, Subodh Verma, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Andrea Glasauer, Andrea Scalise, John J.V. McMurray, Muthiah Vaduganathan, Scott Solomon

Bibliographic record

VenueEuropean Journal of Heart Failure · 2025
Typearticle
Languageen
FieldMedicine
TopicPulmonary Hypertension Research and Treatments
Canadian institutionsCanada Research ChairsUniversity of TorontoSt. Michael's HospitalSurgical Specialties (Canada)
FundersBayer
KeywordsHeart failureMEDLINERandomized controlled trialClinical trialProspective cohort study

Abstract

fetched live from OpenAlex

Abstract Aims While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF occurs across the full spectrum of LVEF. The aim of this study was to assess prevalence, cardiovascular (CV) outcome risk, and treatment response to the non-steroidal mineralocorticoid receptor antagonist finerenone among patients with severe HF in FINEARTS-HF. Methods and results Treatment effects of finerenone on the primary endpoint of total (first and recurrent) HF events and CV death were assessed by severe HF status, as defined by the adapted multiparametric ESC-HFA criteria including New York heart Association functional class III/IV, hospitalization for HF within the previous 12 months, and impairment of health status measured by Kansas City Cardiomyopathy Questionnaire total symptom score <75. Overall, 888 (14.8%) patients fulfilled the definition for severe HF. Patients with severe HF were older, with a higher comorbidity burden, and higher N-terminal pro-B-type natriuretic peptide levels. Over a median follow-up of 2.7 years, total HF events and CV death occurred at a higher rate among those with severe HF (31.6 per 100 patient-years [py]) as compared to those without severe HF (13.9 per 100py). Finerenone was beneficial in reducing the rate of the primary endpoint regardless of severe HF status (pinteraction = 0.98), with a greater absolute rate reduction in those with severe HF (5.9 per 100py) compared with those without severe HF (2.2 per 100py) in light of higher baseline risk. The proportion of patients who discontinued study treatment for any reason or experienced adverse events according to treatment assignment was similar regardless of severe HF status. Conclusions Among patients with mildly reduced or preserved LVEF, severe HF was associated with a heightened risk of CV events. Treatment with finerenone appeared safe and effective, regardless of HF severity.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.251
Teacher spread0.240 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of Heart FailureSame topicPulmonary Hypertension Research and TreatmentsFrench-language works237,207